PIK3CA signaling and pancreatic cancer
PIK3CA 信号传导与胰腺癌
基本信息
- 批准号:10722155
- 负责人:
- 金额:$ 22.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-08 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAnimalsAntibodiesCancer EtiologyCell LineCellsCellular Metabolic ProcessCessation of lifeClinicalClinical TrialsDataDiseaseEnvironmentExhibitsExposure toFDA approvedFlow CytometryGene DeletionGenesGeneticGoalsGrowthHarvestHistocompatibility Antigens Class IHumanHyperlipidemiaHypoxiaImmune EvasionImmune checkpoint inhibitorImmune responseImmune systemImmunocompetentImmunohistochemistryImmunologicsImmunosuppressionImmunotherapeutic agentImmunotherapyImplantInfiltrationKPC modelKRAS oncogenesisKRAS2 geneKRASG12DLaboratoriesLeucocytic infiltrateMHC Class I GenesMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMediatingMetabolicMusMutationNamesOncogenicOperative Surgical ProceduresPIK3CA genePancreasPancreatic Ductal AdenocarcinomaPathway interactionsPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPilot ProjectsPlayProteinsRNAReportingResistanceRoleSCID MiceSignal TransductionT cell infiltrationT cell therapyT-Cell ReceptorT-LymphocyteTarget PopulationsTestingTherapeuticTherapeutic StudiesTreatment ProtocolsUp-RegulationWorkalpelisibanti-PD-1anti-PD1 antibodiescancer cellcancer infiltrating T cellscarboxylatecarboxylationcell typeeffective therapyefficacy testingexhaustionexperimental studygenome-wideimmune checkpointimmune clearanceimplantationimprovedin vivo imaging systemin vivo monitoringinhibitorinstrumentmetabolic profilemethylmalonyl-coenzyme Amouse modelneoplastic cellneutralizing antibodypancreatic cancer cellspancreatic neoplasmpharmacologicprogrammed cell death ligand 1programmed cell death protein 1propionyl-coenzyme Aside effectsingle cell sequencingtherapeutic targettumortumor growthtumor progressiontumor-immune system interactions
项目摘要
The goal of this proposal is to explore how to target PIK3CA signaling for treatment of pancreatic ductal
adenocarcinoma (PDAC). This deadly cancer is highly resistant to current treatment regimens, including
immunotherapy with checkpoint inhibitors. More than 90% of PDAC have oncogenic mutations in KRAS, and
PIK3CA is a direct effector of KRAS. Our group first reported that genetic ablation of PIK3CA in the pancreas
completely protected mice against oncogenic KRAS-induced tumor formation, and subsequently reported that
PIK3CA plays a critical role in sustaining pancreatic tumors by shielding them from the immune system.
Orthotopic implantation of KrasG12D;Trp53R172H;Pdx1-Cre (KPC) pancreatic tumor cells in immunocompetent
mice caused 100% lethality, whereas mice implanted with Pik3ca-/- KPC (PIK3CA-KO) KPC cells exhibited
tumor regression with 100% animal survival. A genome-wide gene deletion screen to search for molecules that
can reverse the elimination of PIK3CA-KO cells by the immune system identified PCCB, which catalyzes the
carboxylation of propionyl-CoA to produce methylmalonyl-CoA. PCCB-null PIK3CA-KO KPC cells were
generated, and when implanted in mice, these tumors were not cleared by the host immune system. Two
hypotheses will be tested: 1) Oncogenic KRAS activation of PIK3CA modulates a PCCB-regulated metabolic
environment that favors evasion of pancreatic cancer from immune elimination; and 2) Alpelisib inhibition of
PIK3CA enhances the activity of anti-PD1 plus anti-PCSK9 therapy against pancreatic tumors. Aim 1
investigates mechanisms by which KRAS activation of PIK3CA modulates a PCCB-regulated metabolic
environment that favors immune evasion of pancreatic cancer, including upregulation of immune checkpoints
and T cell exhaustion. Tumor infiltrating T cells will be isolated and analyzed by single-cell RNA and T cell
receptor (TCR) V(D)J sequencing, flow cytometry and IHC. Adoptive T cell transfer experiments will be
performed to determine if T cells previously exposed to PCCB-null PIK3CA-KO tumors will eliminate PIK3CA-
KO tumors implanted in SCID mice. Cell metabolism and immunological profile of PCCB-null PIK3CA-KO vs.
PIK3CA-KO and parental KPC cell lines will be measured to better understand the metabolic alterations
controlled by PIK3CA and PCCB and how these changes may lead to immune suppression. Aim 2 is a
therapeutic study that tests the efficacy of alpelisib, a PIK3CA inhibitor, in combination with neutralizing
antibodies against PD-1 and PCSK9 for treatment of pancreatic cancer using the orthotopically implanted KPC
mouse model. Tumor infiltrating T cells will also be isolated and analyzed by single-cell sequencing. In
summary, this proposal will investigate how PIK3CA signaling regulates the metabolic and immunological
profile of pancreatic cancer. Alpelisib, anti-PD1 antibodies and anti-PCSK9 antibodies are all FDA-approved for
clinical use. Successful completion of our studies may lead to clinical trials with these approved drugs for
treatment of pancreatic cancer.
该方案的目的是探索如何靶向PIK3CA信号转导治疗胰管疾病。
腺癌(PDAC)。这种致命的癌症对目前的治疗方案高度耐药,包括
使用检查点抑制剂的免疫疗法。超过90%的PDAC在KRAS中存在癌基因突变,并且
PIK3CA是KRAS的直接效应因子。我们小组首次报道了胰腺中PIK3CA的基因消融
完全保护小鼠免受致癌的KRAS诱导的肿瘤形成,随后报道
PIK3CA通过保护胰腺肿瘤免受免疫系统的攻击,在维持胰腺肿瘤的过程中发挥了关键作用。
免疫活性KrasG12D、Trp53R172H、Pdx1-Cre(KPC)胰腺肿瘤细胞的原位移植
小鼠100%致死,而植入PIK3CA-/-KPC(PIK3CA-KO)KPC细胞的小鼠表现出
肿瘤消退,动物存活率100%。一种全基因组的基因缺失屏幕,以搜索
可以逆转免疫系统识别的PCCB对PIK3CA-KO细胞的消除,从而催化
丙酰辅酶A的羧化反应生成甲基丙二酰辅酶A。PCCB阴性的PIK3CA-KO KPC细胞
当移植到小鼠体内时,这些肿瘤不会被宿主免疫系统清除。二
假设将被检验:1)PIK3CA的致癌KRAS激活调节PCCB调节的代谢
有利于胰腺癌从免疫消除中逃脱的环境;以及2)Alpelisib抑制
PIK3CA增强抗PD1+抗PCSK9治疗胰腺肿瘤的活性。目标1
研究PIK3CA的KRAS激活调节PCCB调节的代谢的机制
有利于胰腺癌免疫逃逸的环境,包括上调免疫检查点
和T细胞衰竭。将肿瘤浸润性T细胞分离出来,并用单细胞RNA和T细胞进行分析
受体(TCR)V(D)J测序、流式细胞术和IHC。采用T细胞转移实验将是
以确定先前暴露于PCCB阴性的PIK3CA-KO肿瘤的T细胞是否会消除PIK3CA-KO-
将KO瘤移植到SCID小鼠体内。PCCB缺失的PIK3CA-KO与PIK3CA-KO的细胞代谢和免疫学特性
将测量PIK3CA-KO和亲本KPC细胞系,以更好地了解代谢变化
由PIK3CA和PCCB控制,以及这些变化如何导致免疫抑制。目标2是一个
一项测试PIK3CA抑制剂alpelisib与中和联合治疗效果的治疗研究
抗PD-1和PCSK9抗体原位植入KPC治疗胰腺癌
老鼠模型。肿瘤浸润性T细胞也将被分离并通过单细胞测序进行分析。在……里面
综上所述,本提案将研究PIK3CA信号如何调节代谢和免疫学
胰腺癌的侧写。Alpelisib、抗PD1抗体和抗PCSK9抗体都是FDA批准的用于
临床应用。成功完成我们的研究可能会导致这些批准的药物进行临床试验
胰腺癌的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD Z LIN其他文献
RICHARD Z LIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD Z LIN', 18)}}的其他基金
The role of PI3K in pancreatic cancer genetics and progression
PI3K 在胰腺癌遗传学和进展中的作用
- 批准号:
10266023 - 财政年份:2018
- 资助金额:
$ 22.06万 - 项目类别:
PI3K signaling and channelopathies in the heart
心脏中的 PI3K 信号传导和通道病
- 批准号:
9295021 - 财政年份:2016
- 资助金额:
$ 22.06万 - 项目类别:
Mouse model to study dependence of pancreatic cancer on Pik3ca for progression
研究胰腺癌对 Pik3ca 进展依赖性的小鼠模型
- 批准号:
9188056 - 财政年份:2015
- 资助金额:
$ 22.06万 - 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
- 批准号:
8762239 - 财政年份:2013
- 资助金额:
$ 22.06万 - 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
- 批准号:
8544539 - 财政年份:2013
- 资助金额:
$ 22.06万 - 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
- 批准号:
8966666 - 财政年份:2013
- 资助金额:
$ 22.06万 - 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8003647 - 财政年份:2009
- 资助金额:
$ 22.06万 - 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7525551 - 财政年份:2002
- 资助金额:
$ 22.06万 - 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7645586 - 财政年份:2002
- 资助金额:
$ 22.06万 - 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8064263 - 财政年份:2002
- 资助金额:
$ 22.06万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 22.06万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 22.06万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 22.06万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 22.06万 - 项目类别:
Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
- 批准号:
23KK0126 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 22.06万 - 项目类别:
Training Grant














{{item.name}}会员




